PharmaResearch Products Ltd use call option in Promore Pharma
STOCKHOLM, 17 December 2018 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the company’s partner and third largest shareholder PharmaResearch Products Ltd (PRP) has chosen to exercise the call option granted by the other main shareholders Midroc New Technology AB (Midroc) and Rosetta Capital IV Sarl (Rosetta) in May 2017. The transaction is taking place outside the stock market.PRP has chosen to exercise the call option granted by the other main shareholders Midroc and Rosetta in May 2017. According to an agreement from March